Cargando…

Therapeutics for Graft-versus-Host Disease: From Conventional Therapies to Novel Virotherapeutic Strategies

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) has a curative potential for many hematologic malignancies and blood diseases. However, the success of allo-HSCT is limited by graft-versus-host disease (GVHD), an immunological syndrome that involves inflammation and tissue damage media...

Descripción completa

Detalles Bibliográficos
Autores principales:	Villa, Nancy Y., Rahman, Masmudur M., McFadden, Grant, Cogle, Christopher R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2016
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4810275/ https://www.ncbi.nlm.nih.gov/pubmed/27011200 http://dx.doi.org/10.3390/v8030085

Ejemplares similares

Ex Vivo Oncolytic Virotherapy with Myxoma Virus Arms Multiple Allogeneic Bone Marrow Transplant Leukocytes to Enhance Graft versus Tumor
por: Lilly, Cameron L., et al.
Publicado: (2016)

Role of cytokines in poxvirus host tropism and adaptation
por: Rahman, Masmudur M, et al.
Publicado: (2022)

Virotherapy as Potential Adjunct Therapy for Graft-Vs-Host Disease
por: Villa, Nancy Y., et al.
Publicado: (2018)

Myxoma Virus-Encoded Host Range Protein M029: A Multifunctional Antagonist Targeting Multiple Host Antiviral and Innate Immune Pathways
por: Rahman, Masmudur M., et al.
Publicado: (2020)

Oncolytic Virotherapy for Hematological Malignancies
por: Bais, Swarna, et al.
Publicado: (2012)

Virotherapy Using Myxoma Virus Prevents Lethal Graft-versus-Host Disease following Xeno-Transplantation with Primary Human Hematopoietic Stem Cells
por: Bartee, Eric, et al.
Publicado: (2012)

Assessment of current virotherapeutic application schemes: “hit hard and early” versus “killing softly”?
por: Ruf, Benjamin, et al.
Publicado: (2015)

Modulation of Tumor Necrosis Factor by Microbial Pathogens
por: Rahman, Masmudur M, et al.
Publicado: (2006)

Modulation of NF-κB signalling by microbial pathogens
por: Rahman, Masmudur M., et al.
Publicado: (2011)

Myxoma Virus dsRNA Binding Protein M029 Inhibits the Type I IFN-Induced Antiviral State in a Highly Species-Specific Fashion
por: Rahman, Masmudur M., et al.
Publicado: (2017)

Oncolytic Virotherapy with Myxoma Virus
por: Rahman, Masmudur M., et al.
Publicado: (2020)

Oncolytic Viruses: Newest Frontier for Cancer Immunotherapy
por: Rahman, Masmudur M., et al.
Publicado: (2021)

Identification of host DEAD-box RNA helicases that regulate cellular tropism of oncolytic Myxoma virus in human cancer cells
por: Rahman, Masmudur M., et al.
Publicado: (2017)

Analysis of Vaccinia Virus−Host Protein−Protein Interactions: Validations of Yeast Two-Hybrid Screenings
por: Zhang, Leiliang, et al.
Publicado: (2009)

Myxoma Virus Protein M029 Is a Dual Function Immunomodulator that Inhibits PKR and Also Conscripts RHA/DHX9 to Promote Expanded Host Tropism and Viral Replication
por: Rahman, Masmudur M., et al.
Publicado: (2013)

Myxoma Virus Targets Primary Human Leukemic Stem and Progenitor Cells While Sparing Normal Hematopoietic Stem and Progenitor Cells
por: Kim, Manbok, et al.
Publicado: (2009)

Cytokine determinants of viral tropism
por: McFadden, Grant, et al.
Publicado: (2009)

Co-Regulation of NF-κB and Inflammasome-Mediated Inflammatory Responses by Myxoma Virus Pyrin Domain-Containing Protein M013
por: Rahman, Masmudur M., et al.
Publicado: (2009)

Myxoma Virus-Loaded Mesenchymal Stem Cells in Experimental Oncolytic Therapy of Murine Pulmonary Melanoma
por: Jazowiecka-Rakus, Joanna, et al.
Publicado: (2020)

Oncolytic Virus-Mediated RAS Targeting in Rhabdomyosarcoma
por: Phelps, Michael P., et al.
Publicado: (2018)

Combination of LIGHT (TNFSF14)-Armed Myxoma Virus Pre-Loaded into ADSCs and Gemcitabine in the Treatment of Experimental Orthotopic Murine Pancreatic Adenocarcinoma
por: Jazowiecka-Rakus, Joanna, et al.
Publicado: (2022)

RNA Helicase A/DHX9 Forms Unique Cytoplasmic Antiviral Granules That Restrict Oncolytic Myxoma Virus Replication in Human Cancer Cells
por: Rahman, Masmudur M., et al.
Publicado: (2021)

Combination of the oral histone deacetylase inhibitor resminostat with oncolytic measles vaccine virus as a new option for epi-virotherapeutic treatment of hepatocellular carcinoma
por: Ruf, Benjamin, et al.
Publicado: (2015)

NSCs are permissive to oncolytic Myxoma virus and provide a delivery method for targeted ovarian cancer therapy
por: Cornejo, Yvonne, et al.
Publicado: (2020)

Systemic Delivery of mLIGHT-Armed Myxoma Virus Is Therapeutic for Later-Stage Syngeneic Murine Lung Metastatic Osteosarcoma
por: Christie, John D., et al.
Publicado: (2022)

Autologous Transplantation Using Donor Leukocytes Loaded Ex Vivo with Oncolytic Myxoma Virus Can Eliminate Residual Multiple Myeloma
por: Villa, Nancy.Y., et al.
Publicado: (2020)

Transplantation of autologous bone marrow pre-loaded ex vivo with oncolytic myxoma virus is efficacious against drug-resistant Vk*MYC mouse myeloma
por: Villa, Nancy Y., et al.
Publicado: (2022)

Identification of a Novel Myxoma Virus C7-Like Host Range Factor That Enabled a Species Leap from Rabbits to Hares
por: Águeda-Pinto, Ana, et al.
Publicado: (2022)

The Oncolytic Activity of Myxoma Virus against Soft Tissue Sarcoma Is Mediated by the Overexpression of Ribonucleotide Reductase
por: Woo, Yanghee, et al.
Publicado: (2021)

The Role of Chemokines in Mediating Graft Versus Host Disease: Opportunities for Novel Therapeutics
por: Castor, Marina G. M., et al.
Publicado: (2012)

Myxoma Virus Expressing LIGHT (TNFSF14) Pre-Loaded into Adipose-Derived Mesenchymal Stem Cells Is Effective Treatment for Murine Pancreatic Adenocarcinoma
por: Jazowiecka-Rakus, Joanna, et al.
Publicado: (2021)

Therapeutic effects of hydrogen on chronic graft‐versus‐host disease
por: Qian, Liren, et al.
Publicado: (2017)

Convergent Loss of the Necroptosis Pathway in Disparate Mammalian Lineages Shapes Viruses Countermeasures
por: Águeda-Pinto, Ana, et al.
Publicado: (2021)

Systemic delivery of TNF-armed myxoma virus plus immune checkpoint inhibitor eliminates lung metastatic mouse osteosarcoma
por: Christie, John D., et al.
Publicado: (2021)

Improved Therapeutic Approaches are Needed to Manage Graft-versus-Host Disease
por: Hooker, Deborah S., et al.
Publicado: (2021)

Immunometabolic Therapeutic Targets of Graft-versus-Host Disease (GvHD)
por: Mhandire, Kudakwashe, et al.
Publicado: (2021)

Novel Treatment for Graft-versus-Host Disease
por: Inamoto, Yoshihiro, et al.
Publicado: (2021)

T Cell Subsets in Graft Versus Host Disease and Graft Versus Tumor
por: Jiang, Hua, et al.
Publicado: (2021)

T-Cell Costimulatory Molecules in Acute-Graft-Versus Host Disease: Therapeutic Implications
por: Briones, Javier, et al.
Publicado: (2011)

Therapeutic potential of tranilast for the treatment of chronic graft-versus-host disease in mice
por: Mukai, Shin, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_jc3sm655c2nh2ehcqke7bot5l0